Gain Therapeutics, Inc. (GANX)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 4.1000 |
| Open | 4.0500 |
| Bid | 0.0000 x 1400 |
| Ask | 0.0000 x 800 |
| Day's range | 3.9800 - 4.1881 |
| 52-week range | 2.3300 - 9.7500 |
| Volume | |
| Avg. volume | 61,101 |
| Market cap | 47.638M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4600 |
| Earnings date | 12 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.75 |
- Zacks
Gain Therapeutics, Inc. (GANX) Reports Q2 Loss, Tops Revenue Estimates
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Gain Therapeutics, Inc. (GANX) Expected to Beat Earnings Estimates: Should You Buy?
Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
